You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AKT 3 amplification

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Prostate Cancer, Advanced Solid Tumors Trial in Middletown, Harrison, New York (AZD5363, Enzalutamide,

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Middletown, New Jersey
  • +2 more
Jul 5, 2022

Bile Acids in Acute Insulin Resistance

Recruiting
  • PI3K Gene Mutation
  • +4 more
  • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
  • New York, New York
    Columbia University Medical Center
Oct 6, 2022

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • HS-10241+ Almonertinib
  • Pemetrexed + Cisplatin /Carboplatin
  • (no location specified)
Oct 29, 2023

Cancer, Solid Tumors Trial in United States (Vevorisertib, Fulvestrant, Paclitaxel)

Terminated
Has Results
  • Cancer
  • Solid Tumors
  • Las Vegas, Nevada
  • +5 more
Jun 14, 2022

Everolimus-containing Chemotherapy in HER2- mBC PI3K/AKT/mTOR

Completed
  • Breast Cancer
  • +2 more
  • No intervention, it was a retrospective study.
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 13, 2021

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of

Not yet recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 25, 2023

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +4 more
  • Akt Inhibitor MK2206
  • Laboratory Biomarker Analysis
  • Boston, Massachusetts
  • +6 more
Jan 13, 2022

Distinct Alterations in Gut Microbiota Composition Among Women

Completed
  • Recurrent Miscarriage
    • Hangzhou, China
      Hangzhou First People's Hospital
    Aug 14, 2023

    Solid Tumor, Adult Trial in Seoul (TAS-117)

    Completed
    • Solid Tumor, Adult
    • Seoul, Korea, Republic of
      Severance Hospital, Yonsei University Health System
    Apr 21, 2021

    FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

    Active, not recruiting
    • FGFR1 Gene Amplification
    • +18 more
    • Scottsdale, Arizona
    • +5 more
    Oct 18, 2022

    NSCLC Trial in United States (capmatinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • La Jolla, California
    • +7 more
    Oct 5, 2022

    Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders Trial (ARQ 092)

    No longer available
    • Proteus Syndrome
    • +2 more
    • ARQ 092
    • (no location specified)
    Jul 31, 2021

    Solid Tumor, Haematological Malignancy, Colorectal Tumors Trial in United Kingdom (Trastuzumab, Pertuzumab)

    Recruiting
    • Solid Tumor
    • +10 more
    • Belfast, United Kingdom
    • +25 more
    Mar 28, 2023

    FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic

    Not yet recruiting
    • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
    • +4 more
    • Computed Tomography
    • +3 more
    • (no location specified)
    Sep 13, 2022

    Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

    Recruiting
    • Breast Neoplasm
    • +4 more
    • PIK3CA inhibitor
    • +12 more
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jan 2, 2023

    Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)

    Recruiting
    • Metastatic Breast Cancer
    • Badalona, Barcelona, Spain
    • +9 more
    Oct 24, 2022

    Breast Cancer Trial in Beijing (Inetetamab, Rapamycin, Pyrotinib)

    Not yet recruiting
    • Breast Cancer
    • Beijing, China
      National Cancer Center/National Clinical Research Center for Can
    Jan 31, 2021

    Squamous Cell Lung Cancer Trial in United States (ZEN003694)

    Recruiting
    • Squamous Cell Lung Cancer
    • Basking Ridge, New Jersey
    • +6 more
    Nov 1, 2022

    Malignant Solid Tumor Trial in Philadelphia (Biopsy, Biospecimen Collection, Echocardiography)

    Active, not recruiting
    • Malignant Solid Neoplasm
    • Biopsy
    • +5 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Nov 15, 2023

    Carcinoma, Squamous Cell of Head and Neck Trial in France (Copanlisib, Cetuximab)

    Terminated
    • Carcinoma, Squamous Cell of Head and Neck
    • Angers, France
    • +6 more
    Mar 24, 2021

    Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification Trial in Worldwide (Futibatinib, Futibatinib plus

    Recruiting
    • Metastatic Breast Cancer
    • +2 more
    • Phoenix, Arizona
    • +36 more
    Jan 27, 2023

    Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick

    Active, not recruiting
    • Advanced Malignant Solid Neoplasm
    • +9 more
    • New Brunswick, New Jersey
      Rutgers Cancer Institute of New Jersey
    Jan 25, 2023

    Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

    Recruiting
    • Bladder Cancer
    • +12 more
    • Raleigh, North Carolina
      xCures Virtual Site
    Sep 20, 2021